AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.
AZN Key Statistics
Stock Snapshot
With a market cap of 299.43B, AstraZeneca(AZN) trades at $193.08. The stock has a price-to-earnings ratio of 29.44 and currently yields dividends of 1.6%.
On 2026-03-09, AstraZeneca(AZN) stock moved within a range of $187.99 to $193.92. With shares now at $193.08, the stock is trading +2.7% above its intraday low and -0.4% below the session's peak.
Trading volume for AstraZeneca(AZN) stock has reached 1.09M, versus its average volume of 2.07M.
The stock's 52-week range extends from a low of $122.48 to a high of $212.71.
The stock's 52-week range extends from a low of $122.48 to a high of $212.71.
AZN News
Daiichi Sankyo and AstraZeneca’s (AZN) supplemental biologics license application for Enhertu has been accepted and granted priority review in the U.S. for the...
(RTTNews) - Daiichi Sankyo (4568.T) and AstraZeneca's (AZN, AZN.L, ZEG.DE, AZN.ST) supplemental Biologics License Application for ENHERTU has been accepted and...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca (GB:AZN) has launched a Phase I trial titled “A Phase I, Randomized,...
Analyst ratings
81%
of 31 ratingsMore AZN News
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca’s latest update covers ALAFOSS-01, a first-in-human Phase I/IIa trial of A...
AstraZeneca ( (GB:AZN) ) has shared an update. AstraZeneca disclosed that Chief Executive Officer Pascal Soriot received an allocation of 101,495 ordinary shar...
Thursday, March 5, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports...
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca is updating investors on a phase I trial testing a new drug mix in tough-t...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca (GB:AZN) has launched a Phase I trial titled “A Phase I Randomized Si...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. The study “Open-label Single-arm, Non-interventional, Multi-centre Study for Eval...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca has started a new early-stage trial to see how its zibotentan/dapagli...